Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]
News [2526]
Articles [155]
Editorials [8]
Conferences [103]
elearning [18]
Welcome to APCCC 2021
Prof Silke Gillessen and Prof Aurelius Omlin
Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )
23 Sep 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021
PARP inhibitors in prostate cancer: Case based testing and clinical decisions
Dr Neal Shore and Prof Fred Saad
PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
20 Sep 2021
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25%...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
19 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
19 Sep 2021
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic...
Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer ( Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom )
19 Sep 2021
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of...
Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC ( Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK )
19 Sep 2021
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally...
Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer ( Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands )
18 Sep 2021
Cabozantinib in combination with atezolizumab in patients with mCRPC
Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty...
Cabozantinib in combination with atezolizumab in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, USA )
18 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Sep 2021
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or...
Prof Thomas Powles - Queen Mary University of London, London, UK
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )
17 Sep 2021

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation